Abstract
Summary
The global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Chimeric Antigen Receptor (CAR)-T Cell Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Chimeric Antigen Receptor (CAR)-T Cell Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Chimeric Antigen Receptor (CAR)-T Cell Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Chimeric Antigen Receptor (CAR)-T Cell Therapy players cover Autolus Therapeutics, CARsgen Therapeutics, Juno Therapeutics, Sorrento Therapeutics, bluebird bio, CELGENE CORPORATION, Eureka Therapeutics, Avacta Life Sciences and Calyxt, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Chimeric Antigen Receptor (CAR)-T Cell Therapy Industry Forecast” looks at past sales and reviews total world Chimeric Antigen Receptor (CAR)-T Cell Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Chimeric Antigen Receptor (CAR)-T Cell Therapy sales for 2023 through 2029. With Chimeric Antigen Receptor (CAR)-T Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chimeric Antigen Receptor (CAR)-T Cell Therapy industry.
This Insight Report provides a comprehensive analysis of the global Chimeric Antigen Receptor (CAR)-T Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chimeric Antigen Receptor (CAR)-T Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chimeric Antigen Receptor (CAR)-T Cell Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chimeric Antigen Receptor (CAR)-T Cell Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chimeric Antigen Receptor (CAR)-T Cell Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of Chimeric Antigen Receptor (CAR)-T Cell Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Abecma
Breyanzi
Kymriah
Tecartus
Yescarta
Others
Segmentation by application
Hospital
Diagnostic Center
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Autolus Therapeutics
CARsgen Therapeutics
Juno Therapeutics
Sorrento Therapeutics
bluebird bio
CELGENE CORPORATION
Eureka Therapeutics
Avacta Life Sciences
Calyxt
Celyad Oncology SA
Fortress Biotech
IMMUNE THERAPEUTICS
Gilead Sciences
Novartis AG
Alaunos Therapeutics
Poseida Therapeutics
United States market for Chimeric Antigen Receptor (CAR)-T Cell Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Chimeric Antigen Receptor (CAR)-T Cell Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Chimeric Antigen Receptor (CAR)-T Cell Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Chimeric Antigen Receptor (CAR)-T Cell Therapy players cover Autolus Therapeutics, CARsgen Therapeutics, Juno Therapeutics, Sorrento Therapeutics, bluebird bio, CELGENE CORPORATION, Eureka Therapeutics, Avacta Life Sciences and Calyxt, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Chimeric Antigen Receptor (CAR)-T Cell Therapy Industry Forecast” looks at past sales and reviews total world Chimeric Antigen Receptor (CAR)-T Cell Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Chimeric Antigen Receptor (CAR)-T Cell Therapy sales for 2023 through 2029. With Chimeric Antigen Receptor (CAR)-T Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chimeric Antigen Receptor (CAR)-T Cell Therapy industry.
This Insight Report provides a comprehensive analysis of the global Chimeric Antigen Receptor (CAR)-T Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chimeric Antigen Receptor (CAR)-T Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chimeric Antigen Receptor (CAR)-T Cell Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chimeric Antigen Receptor (CAR)-T Cell Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chimeric Antigen Receptor (CAR)-T Cell Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of Chimeric Antigen Receptor (CAR)-T Cell Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Abecma
Breyanzi
Kymriah
Tecartus
Yescarta
Others
Segmentation by application
Hospital
Diagnostic Center
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Autolus Therapeutics
CARsgen Therapeutics
Juno Therapeutics
Sorrento Therapeutics
bluebird bio
CELGENE CORPORATION
Eureka Therapeutics
Avacta Life Sciences
Calyxt
Celyad Oncology SA
Fortress Biotech
IMMUNE THERAPEUTICS
Gilead Sciences
Novartis AG
Alaunos Therapeutics
Poseida Therapeutics
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2018-2029
2.1.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Segment by Type
2.2.1 Abecma
2.2.2 Breyanzi
2.2.3 Kymriah
2.2.4 Tecartus
2.2.5 Yescarta
2.2.6 Others
2.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type
2.3.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type (2018-2023)
2.4 Chimeric Antigen Receptor (CAR)-T Cell Therapy Segment by Application
2.4.1 Hospital
2.4.2 Diagnostic Center
2.4.3 Other
2.5 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application
2.5.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Application (2018-2023)
3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Player
3.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Players
3.1.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Players (2018-2023)
3.1.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Chimeric Antigen Receptor (CAR)-T Cell Therapy by Regions
4.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Regions (2018-2023)
4.2 Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth (2018-2023)
4.3 APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth (2018-2023)
4.4 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth (2018-2023)
4.5 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth (2018-2023)
5 Americas
5.1 Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2018-2023)
5.2 Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2018-2023)
5.3 Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region (2018-2023)
6.2 APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2018-2023)
6.3 APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy by Country (2018-2023)
7.2 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2018-2023)
7.3 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy by Region (2018-2023)
8.2 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2018-2023)
8.3 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Regions (2024-2029)
10.1.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Regions (2024-2029)
10.1.2 Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast
10.1.3 APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast
10.1.4 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast
10.1.5 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast
10.2 Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Country (2024-2029)
10.2.1 United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.2.2 Canada Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.2.3 Mexico Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.2.4 Brazil Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.3 APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Region (2024-2029)
10.3.1 China Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.3.2 Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.3.3 Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.3.4 Southeast Asia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.3.5 India Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.3.6 Australia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.4 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Country (2024-2029)
10.4.1 Germany Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.4.2 France Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.4.3 UK Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.4.4 Italy Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.4.5 Russia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.5 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Region (2024-2029)
10.5.1 Egypt Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.5.2 South Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.5.3 Israel Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.5.4 Turkey Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.5.5 GCC Countries Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.6 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Type (2024-2029)
10.7 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Autolus Therapeutics
11.1.1 Autolus Therapeutics Company Information
11.1.2 Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.1.3 Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Autolus Therapeutics Main Business Overview
11.1.5 Autolus Therapeutics Latest Developments
11.2 CARsgen Therapeutics
11.2.1 CARsgen Therapeutics Company Information
11.2.2 CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.2.3 CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 CARsgen Therapeutics Main Business Overview
11.2.5 CARsgen Therapeutics Latest Developments
11.3 Juno Therapeutics
11.3.1 Juno Therapeutics Company Information
11.3.2 Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.3.3 Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Juno Therapeutics Main Business Overview
11.3.5 Juno Therapeutics Latest Developments
11.4 Sorrento Therapeutics
11.4.1 Sorrento Therapeutics Company Information
11.4.2 Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.4.3 Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Sorrento Therapeutics Main Business Overview
11.4.5 Sorrento Therapeutics Latest Developments
11.5 bluebird bio
11.5.1 bluebird bio Company Information
11.5.2 bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.5.3 bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 bluebird bio Main Business Overview
11.5.5 bluebird bio Latest Developments
11.6 CELGENE CORPORATION
11.6.1 CELGENE CORPORATION Company Information
11.6.2 CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.6.3 CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 CELGENE CORPORATION Main Business Overview
11.6.5 CELGENE CORPORATION Latest Developments
11.7 Eureka Therapeutics
11.7.1 Eureka Therapeutics Company Information
11.7.2 Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.7.3 Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Eureka Therapeutics Main Business Overview
11.7.5 Eureka Therapeutics Latest Developments
11.8 Avacta Life Sciences
11.8.1 Avacta Life Sciences Company Information
11.8.2 Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.8.3 Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Avacta Life Sciences Main Business Overview
11.8.5 Avacta Life Sciences Latest Developments
11.9 Calyxt
11.9.1 Calyxt Company Information
11.9.2 Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.9.3 Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Calyxt Main Business Overview
11.9.5 Calyxt Latest Developments
11.10 Celyad Oncology SA
11.10.1 Celyad Oncology SA Company Information
11.10.2 Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.10.3 Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Celyad Oncology SA Main Business Overview
11.10.5 Celyad Oncology SA Latest Developments
11.11 Fortress Biotech
11.11.1 Fortress Biotech Company Information
11.11.2 Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.11.3 Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Fortress Biotech Main Business Overview
11.11.5 Fortress Biotech Latest Developments
11.12 IMMUNE THERAPEUTICS
11.12.1 IMMUNE THERAPEUTICS Company Information
11.12.2 IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.12.3 IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 IMMUNE THERAPEUTICS Main Business Overview
11.12.5 IMMUNE THERAPEUTICS Latest Developments
11.13 Gilead Sciences
11.13.1 Gilead Sciences Company Information
11.13.2 Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.13.3 Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Gilead Sciences Main Business Overview
11.13.5 Gilead Sciences Latest Developments
11.14 Novartis AG
11.14.1 Novartis AG Company Information
11.14.2 Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.14.3 Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Novartis AG Main Business Overview
11.14.5 Novartis AG Latest Developments
11.15 Alaunos Therapeutics
11.15.1 Alaunos Therapeutics Company Information
11.15.2 Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.15.3 Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Alaunos Therapeutics Main Business Overview
11.15.5 Alaunos Therapeutics Latest Developments
11.16 Poseida Therapeutics
11.16.1 Poseida Therapeutics Company Information
11.16.2 Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.16.3 Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Poseida Therapeutics Main Business Overview
11.16.5 Poseida Therapeutics Latest Developments
12 Research Findings and Conclusion